공지 • May 28
Biocure Technology Inc., Annual General Meeting, Jul 30, 2025 Biocure Technology Inc., Annual General Meeting, Jul 30, 2025. Location: british columbia, vancouver Canada 공지 • Apr 22
Biocure Technology Inc. announced that it expects to receive CAD 0.15 million in funding Biocure Technology Inc. announced a non-brokered private placement financing of up to 7,500,000 units at CAD 0.02 per Unit of the Company for aggregate proceeds of up to CAD 150,000 on April 21, 2025. Each Unit will consist of one 1 common share in the capital of the Company and one
transferrable common share purchase warrant. Each Warrant entitles the holder thereof to purchase one Share at a price of CAD 0.05 for a period of five (5) years from the date of issuance. The issuance of securities in connection with this Offering will be subject to Canadian Securities Exchange (“CSE”) approval and the securities will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable Canadian securities laws. 공지 • Dec 20
Biocure Technology Inc. announced that it expects to receive CAD 0.2 million in funding Biocure Technology Inc. announced a non-brokered financing to raise 10,000,000 common shares at an issue price of CAD 0.02 per share for the gross proceeds of CAD 200,000 on December 19, 2024. No finders' fees are expected to be paid on any portion of the placement. No new insiders or control persons are expected to be created as a result of the placement. Existing insiders of the company are expected to participate in the placement. Board Change • Sep 30
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공지 • Sep 10
Biocure Technology Inc. Announces Chief Executive Officer Changes Biocure Technology Inc. announced resignation of Sang Mok Lee as chief executive officer. The company is also pleased to announce that Yee Sing (Simon) Cheng has been appointed as CEO. Mr. Cheng has over 10 years of experience of innovation and success in the technology and finance sector. His focus is on program development, with an emphasis on capital finance, business agreement negotiations and corporate development. He previously held positions with professional investment firms providing advisory services to high-net-worth individuals and institutional investors. 공지 • Sep 09
Biocure Technology Inc. Announces Board of Director Changes Biocure Technology Inc. announced resignation of Sang Mok Lee from the board of directors. The company is also pleased to announce that Yee Sing (Simon) Cheng has been appointed to the board of directors. Mr. Cheng has over 10 years of experience of innovation and success in the technology and finance sector. His focus is on program development, with an emphasis on capital finance, business agreement negotiations and corporate development. He previously held positions with professional investment firms providing advisory services to high-net-worth individuals and institutional investors. Board Change • Jul 18
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 1 independent director (2 non-independent directors). Independent Director Collin Kim was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공지 • Jul 06
Biocure Technology Inc. Announces That Berkan Unal Has Resigned from Its Board of Directors Biocure Technology Inc. announced that Berkan Unal has resigned from its board of directors. The Company will be seeking suitable candidates to enhance the composition of the board of directors in the future. 공지 • Feb 01
Biocure Technology Inc. announced that it has received CAD 0.2376 million in funding Biocure Technology Inc. announced a non-brokered private placement of 55,000 shares at an issue price of CAD 4.32 per share for gross proceeds of CAD 237,600 on January 30, 2023. The company holds now 92.10% interest in BPK. 공지 • Jan 18
Biocure Technology Inc. announced that it has received CAD 0.0541 million in funding Biocure Technology Inc. announced a non-brokered private placement of 12,500 shares at an issue price of CAD 4.328 per share for gross proceeds of CAD 54,100 on January 17, 2023. The company holds now 93.42% interest in BPK. 공지 • Dec 23
Biocure Technology Inc. Announces Danny Joh Resigned from Board of Directors Biocure Technology Inc. announced that Danny Joh has resigned from its board of directors. The Company would like to thank Mr. Joh for his contributions to the Company and wish him all the best for the future. The Company will be seeking for a suitable candidate to enhance the composition of the board of director. 공지 • May 21
Biocure Technology Inc., Annual General Meeting, Jul 25, 2022 Biocure Technology Inc., Annual General Meeting, Jul 25, 2022. 공지 • Jul 15
Biocure Technology Inc. announced that it has received CAD 1.073044 million in funding Biocure Technology Inc. announced a non-brokered private placement of 6,706,525 units at a price of CAD 0.16 per unit for gross proceeds of CAD 1,073,044 on July 14, 2021. Each unit comprised of one common share and one share purchase warrant of the company, where each whole warrant entitles the holder to purchase an additional share for a period of two years from closing, at a price of CAD 0.21 per warrant share. The company has also agreed to pay a finder's fee of 8% in cash and 8% in warrants for the proceeds raised by the finders in the transaction. Each finder warrants entitles the holder to purchase an additional share for a period of two years from closing, at a price of CAD 0.21 per warrant share. All finder fees are subject to CSE approval. Executive Departure • Feb 23
Independent Director has left the company On the 16th of February, Hans Frykman's tenure as Independent Director ended after 2.5 years in the role. We don't have any record of a personal shareholding under Hans' name. Hans is the only executive to leave the company over the last 12 months. 공지 • Feb 17
Biocure Technology Inc. Announces Board Changes Biocure Technology Inc. announced that Mr. Berkan Unal has joined the Board of Directors as an Independent Director, effective immediately. He will replace Mr. Hans Frykman, whom was a valuable asset to the company's board for 3 years. Currently, he is acting and will continue, as the Business Development Director for Biologics, Gene and Cell Therapy of GenScript Biotech. 공지 • Jan 06
Biocure Technology Corp. Enters into MOU with Symbasis GmbH Biocure Technology Corp. announced that BPK has entered into a MOU with Symbasis GmbH. They have expressed a common interest in developing a CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL) and wish to sign this MOU for the purpose of confirming their intention in respect to the development. The purpose of this MOU is to establish a Joint Venture in Germany under the name "Oncocart" for clinical trials, production and marketing in Europe, (potentially, including other regions of the world) of ROR1-based products for the CAR-T therapy the target indication of which is CLL. The MOU is intended to form the basis of discussions and negotiations between the Parties for the purpose of entering into final agreements without creating any obligation to do so. Both parties agree that this Joint Venture will enable them to bring together an extremely experienced group of experts and professionals, allowing for all phases of the development to advance more effectively. Is New 90 Day High Low • Dec 24
New 90-day high: CA$0.20 The company is up 3.0% from its price of CA$0.20 on 25 September 2020. The Canadian market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 6.0% over the same period. 공지 • Oct 15
Biocure Technology Inc. announced that it expects to receive CAD 0.250142 million in funding Biocure Technology Inc. (CNSX:CURE) announced a non-brokered private placement of 1,786,725 units at a price of CAD 0.14 per unit for gross proceeds CAD 250,142 on October 14, 2020. Each unit consists of one common share and one share purchase pursuant. Each warrant entitles the holder to purchase an additional share for a period of two years from closing at a price of CAD 0.21 per warrant share. The company has also agreed to pay finder's fees of CAD 3,360 and 24,000 finder warrants for the proceeds raised by the finders. The transaction is expected to close on October 15, 2020. All securities issued in the transaction have a hold period of February 15, 2021.